Prospective Study of FMT for Acute Intestinal GVHD After Allo-HSCT

• Status: Recruiting
• Trial end date: 2023-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Acute intestinal GVHD is the main cause of death after allo-HSCT, and FMT is a new treatment method for this disease. In this prospective study, the investigators will recruit intestinal GVHD patients to demonstrate the efficacy and safety of FMT.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Qilu Hospital of Shandong University
• Collaborator: Peking University People's Hospital

Criteria

Inclusion Criteria:

1. received allo-HSCT due to a hematopoietic disease

2. corticosteroid resistant/dependent intestinal GVHD

3. ECOG≤2

4. Sign informed Consent

5. No major organ dysfunction

Exclusion Criteria:

1. uncontrolled or severe infections

2. patients with severe liver and kidney function, cardiopulmonary insufficiency, epilepsy, and central nervous system disorder

3. high-risk bleeding

4. ANC<0.5×10^9/L or PLT<20x10^9/L

5. hepatitis B, tuberculosis, syphilis, and HIV antibody positive or acute phase of any infectious disease

6. patients participating in other clinical trials

7. patienta who suffer from mental illness